Tissue Regenix launch product line extension DermaPure Non-Oriented
Francesca Morgan
Company News - 2 mins
08:10, 3rd October 2019

Regenerative medical devices company. Tissue Regenix Group (TRX) FOLLOW, announced on Thursday the launch of a product line extension, 'DermaPure Non- Oriented', an expansion of its flagship dCELL® Technology product, DermaPure.

DermaPure Non-Oriented, a product specifically tailored for the surgical and trauma markets, was unveiled at the American Urogynecologic Society, an annual meeting in Nashville last week, the company revealed. 

The product, which is now available for distribution, is processed using dCELL® Technology and has two identical sides -- meaning the orientation of the graft is not a factor therefore enhancing the ease of application.

The primary indication for this product line will be uro-gynecological procedures, where Tissue Regenix have already established a strong working relationship with partner and specialist distributor, ARMS Medical.

Interim Chief Executive of Tissue Regenix Group, Gareth Jones, commented: 

"Our commercial success is predicated on our ability to identify new clinical applications and rapidly develop product lines to meet this demand. 

Working closely with our strategic partner, ARMS Medical, we are confident that DermaPure Non-Oriented will offer our clinicians the clinical outcomes and health economic benefits they require. 

We continue to see the growing demand for DermaPure, as demonstrated in our recent interim results, and expect that DermaPure Non-Oriented will augment this product portfolio, driving adoption by physicians in the future."

Follow News & Updates from Tissue Regenix Group here: FOLLOW

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Comments
info
Login or register to post comments

Recent Articles
Watchlist